Erschienen in:
06.02.2019 | Editorial
New insights for early assessment of cardiac involvement in Anderson-Fabry disease
verfasst von:
Alberto Cuocolo, MD, Carmela Nappi, MD, Valeria Gaudieri, MD, PhD, Antonio Pisani, MD, PhD, Massimo Imbriaco, MD
Erschienen in:
Journal of Nuclear Cardiology
|
Ausgabe 6/2021
Einloggen, um Zugang zu erhalten
Excerpt
Anderson-Fabry disease (AFD) is an X-linked recessive lysosomal storage disorder that is caused by the deficient activity of a-galactosidase A (a-Gal A)
1 with the resultant accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids
2 in a variety of cells, including micro-vascular endothelial cells, renal tubular cells, and myocardial cells. In classically affected males, the progressive Gb3 accumulation leads to renal, cardiac, and cerebro-vascular manifestations and early death.
3 Chronic renal failure represents the most frequent cause of morbidity, with cardiac involvement being the leading cause of death and premature mortality.
4 It has been reported that the progressive accumulation of Gb3 in cardiomyocytes, cardiac valves, endothelial cells, and conduction system, leads to increased ventricular wall thickness and functional impairment,
5 in addition to valvular and electrocardiographic abnormalities.
6 The classic cardiac involvement is a form of hypertrophic cardiomyopathy, usually described as concentric left ventricular hypertrophy (LVH). The disease is progressive, with symptoms appearing with increasing age. …